Skip to content
Screener

Net debt / EBITDA at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
9.5×+8.9×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
0.3×+0.2×
Theravance Biopharma logo
Theravance BiopharmaTBPH
-84.1×
XER
Xeris Biopharma Holdings, Inc.XERS
4.4×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
7.6×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-0.2×-1.4×

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+7.3%
Enterprise value$561.65M-17.1%
P/E12.1×-237×
P/S5.2×-5.4×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Calculated from Zevra Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068

FAQ

What is Zevra Therapeutics, Inc.'s net debt / EBITDA?
Zevra Therapeutics, Inc. (ZVRA) reported net debt / EBITDA of -1.6× in Q2 2026.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ask your AI about Zevra Therapeutics, Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude